Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study (Q33371653)

26 July 2017

Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study (English)

1 reference

26 July 2017

Barker JN

8

0 references

author name string

Smith CH

1

1 reference

26 July 2017

Jackson K

2

1 reference

26 July 2017

Bashir SJ

3

1 reference

26 July 2017

Perez A

4

1 reference

26 July 2017

Chew AL

5

1 reference

26 July 2017

Powell AM

6

1 reference

26 July 2017

Wain M

7

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 July 2006

1 reference

British Journal of Dermatology

26 July 2017

1 reference

26 July 2017

155

1 reference

26 July 2017

1

1 reference

26 July 2017

160-169

1 reference

Physical and psychologic measures are necessary to assess overall psoriasis severity

26 July 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

Quality of life issues in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

Psoriasis causes as much disability as other major medical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

Methotrexate in psoriasis: consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

Measures of Clinical Severity, Quality of Life, and Psychological Distress in Patients with Psoriasis: A Cluster Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

Psoriasis Is Common, Carries a Substantial Burden Even When Not Extensive, and Is Associated with Widespread Treatment Dissatisfaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

Tuberculosis and treatment with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

Granulomatous infections due to tumor necrosis factor blockade: correction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07316.X

10.1111/J.1365-2133.2006.07316.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference